ProCE Banner Activity

Avatrombopag in Chronic ITP: Assessment of Gastric Toxicity in 2 Phase III Studies

Slideset Download
Conference Coverage
In this analysis of gastric biomarkers from 2 phase III trials, no significant gastric toxicity was associated with the use of avatrombopag to treat thrombocytopenia in patients with chronic ITP.

Released: December 06, 2018

Expiration: December 05, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology